These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6487491)

  • 1. The effect of acetylator phenotype on the disposition of aminoglutethimide.
    Adam AM; Rogers HJ; Amiel SA; Rubens RD
    Br J Clin Pharmacol; 1984 Oct; 18(4):495-505. PubMed ID: 6487491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphically acetylated aminoglutethimide in humans.
    Coombes RC; Foster AB; Harland SJ; Jarman M; Nice EC
    Br J Cancer; 1982 Sep; 46(3):340-5. PubMed ID: 7126424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylation polymorphism of dapsone in a Japanese population.
    Horai Y; Ishizaki T
    Br J Clin Pharmacol; 1988 Apr; 25(4):487-94. PubMed ID: 3382590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylation phenotyping using dapsone in a Jordanian population.
    Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM
    Br J Clin Pharmacol; 1991 Sep; 32(3):289-93. PubMed ID: 1777365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetylation phenotyping with dapsone in a mainland Chinese population.
    Horai Y; Zhou HH; Zhang LM; Ishizaki T
    Br J Clin Pharmacol; 1988 Jan; 25(1):81-7. PubMed ID: 3370194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of age, sex and body weight on the dapsone acetylation phenotype.
    Philip PA; Gayed SL; Rogers HJ; Crome P
    Br J Clin Pharmacol; 1987 Jun; 23(6):709-13. PubMed ID: 3606931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of dapsone and acetylated dapsone in serum and saliva.
    Lammintausta K; Kangas L; Lammintausta R
    Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):159-63. PubMed ID: 447435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.
    Horai Y; Ishizaki T; Sasaki T; Koya G; Matsuyama K; Iguchi S
    Br J Clin Pharmacol; 1982 Mar; 13(3):361-74. PubMed ID: 7059436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic observations on dapsone in dermatitis herpetiformis.
    Swain AF; Ahmad RA; Rogers HJ; Leonard JN; Fry L
    Br J Dermatol; 1983 Jan; 108(1):91-8. PubMed ID: 6821646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of acetylator phenotype of the leprosy patient on the emergence of dapsone resistant leprosy.
    Raj PP; Aschhoff M; Lilly L; Balakrishnan S
    Indian J Lepr; 1988 Jul; 60(3):400-6. PubMed ID: 3058828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the acetylator phenotype on amrinone pharmacokinetics.
    Hamilton RA; Kowalsky SF; Wright EM; Cernak P; Benziger DP; Stroshane RM; Edelson J
    Clin Pharmacol Ther; 1986 Dec; 40(6):615-9. PubMed ID: 3780123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglutethimide therapy in breast cancer: relationship of blood levels to drug-related side effects.
    Demers LM; Boucher AE; Santen RJ
    Clin Physiol Biochem; 1987; 5(5):287-91. PubMed ID: 3652603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acedapsone treatment of leprosy patients: response versus drug disposition.
    Peters JH; Murray JF; Gordon GR; Levy L; Russell DA; Scott GC; Vincin DR; Shepard CC
    Am J Trop Med Hyg; 1977 Jan; 26(1):127-36. PubMed ID: 842774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer.
    Miller AA; Miller BE; Höffken K; Schmidt CG
    Cancer Chemother Pharmacol; 1987; 20(4):337-41. PubMed ID: 3690808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylation of dapsone by human whole blood.
    Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM; Gharaibeh NS
    Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):18-22. PubMed ID: 8444513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.
    Reece PA; Cozamanis I; Zacest R
    Eur J Clin Pharmacol; 1982; 23(6):523-7. PubMed ID: 7160421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The disposition of dapsone and monoacetyldapsone in the dog (38516).
    Peters JH; Gordon R; Biggs JT; Levy L
    Proc Soc Exp Biol Med; 1975 Jan; 148(1):251-5. PubMed ID: 1129265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between the metabolism of procainamide and sulfamethazine.
    Giardina E-GV ; Stein RM; Bigger JT
    Circulation; 1977 Feb; 55(2):388-94. PubMed ID: 832354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma kinetics of dipyrone metabolites in rapid and slow acetylators.
    Levy M; Flusser D; Zylber-Katz E; Granit L
    Eur J Clin Pharmacol; 1984; 27(4):453-8. PubMed ID: 6519153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.